Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) & Ultragenyx Pharmaceutical (NASDAQ:RARE)

Cyclerion Therapeutics (NASDAQ:CYCN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Earnings & Valuation

This table compares Cyclerion Therapeutics and Ultragenyx Pharmaceutical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$1.62 million	4.88	-$5.26 million	N/A	N/A
Ultragenyx Pharmaceutical	$434.25 million	11.61	-$606.64 million	($7.30)	-7.49

Cyclerion Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Risk and Volatility

Cyclerion Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 13.1% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cyclerion Therapeutics and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	N/A	-66.84%	-57.28%
Ultragenyx Pharmaceutical	-121.57%	-266.02%	-41.39%

Analyst Recommendations

This is a breakdown of recent recommendations for Cyclerion Therapeutics and Ultragenyx Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	0	0	0	0	N/A
Ultragenyx Pharmaceutical	0	1	13	0	2.93

Ultragenyx Pharmaceutical has a consensus target price of $88.29, indicating a potential upside of 61.43%. Given Ultragenyx Pharmaceutical’s higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Cyclerion Therapeutics.

Summary

Ultragenyx Pharmaceutical beats Cyclerion Therapeutics on 6 of the 11 factors compared between the two stocks.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.